The startup says it’s creating a technology-enabled platform to “make clinical trials a care option for all patients.” Paradigm also acquired Deep Lens, a company that uses EHR and genomics data to recruit oncology patients for clinical trials.
“By rethinking how clinical trials are conducted and reducing the burden on health systems for participation, they’re democratizing access to clinical trials,” said Hemant Taneja, CEO and managing director of General Catalyst and board co-chair for Paradigm, in a news release.
Paradigm’s board of directors also includes Stephen Klasko, MD, an executive-in-residence at General Catalyst and the former president and CEO of Philadelphia-based Jefferson Health.
The financing round was co-led by Arch Venture Partners and also featured the American Cancer Society’s BrightEdge fund.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
